Status:
ACTIVE_NOT_RECRUITING
A Study of IBI3032 in Chinese Participants With Overweight or Obesity
Lead Sponsor:
Innovent Biologics Technology Limited (Shanghai R&D Center)
Conditions:
Overweight or Obesity
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI30...
Eligibility Criteria
Inclusion
- Healthy male or females, as determined by medical history
- Have safety laboratory results within normal reference ranges
Exclusion
- Have known allergies toIBI3032， glucagon-like peptide-1 (GLP-1) analogs, related compounds
- Abnormal electrocardiogram (ECG) at screening
- Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders.
Key Trial Info
Start Date :
September 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2026
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT07170319
Start Date
September 25 2025
End Date
March 31 2026
Last Update
December 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Frist Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China, 230000